MedTech Dive December 13, 2023
Integra said the purchase, which includes a portfolio of balloon dilation products for the sinuses and eustachian tube, would make it a market leader in ENT procedures.
Dive Brief:
- Integra Lifesciences reached an agreement to buy Johnson & Johnson’s ear, nose and throat (ENT) subsidiary Acclarent for $275 million in cash, the company announced Wednesday.
- Integra CEO Jan De Witte said the acquisition provides “a rare opportunity to become a key player in the ENT segment.”
- For J&J, the divestment comes as the company looks to focus its medtech portfolio on the highest growth segments.
Dive Insight:
Princeton, New Jersey-based Integra largely sells neurosurgery devices, but it also has a line of surgical instruments for ENT...
Today's Sponsors
Today's Sponsor